Royal Bank of Canada
AZN icon

Royal Bank of Canada’s AstraZeneca AZN Stock Holding History

Royal Bank of Canada’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-50
Closed -$4K – 6690
2019
Q2 		$4K Sell
50
-50
-50% -$3.92K ﹤0.01% 6374
2019
Q1 		$8K Buy
+100
New +$7.88K ﹤0.01% 6074

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Royal Bank of Canada's AZN Position: Q1 2026 in Review

Royal Bank of Canada increased its AstraZeneca (AZN) stake by 517% in Q1 2026, buying an estimated $1.68B and bringing the position to 10,386,455 shares worth $2.05B. The position accounts for 0.36% of the portfolio, ranked #52.

Royal Bank of Canada first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,382 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Royal Bank of Canada held 10,386,455 shares of AstraZeneca worth $2.05B as of Q1 2026.
  • Royal Bank of Canada bought 8,703,790 AstraZeneca shares in Q1 2026, an estimated $1.68B.
  • AstraZeneca made up 0.36% of Royal Bank of Canada's portfolio in Q1 2026, its #52 holding.
  • Royal Bank of Canada first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • 1,382 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.